CN103957910A - 增加先天免疫反应的化合物和方法 - Google Patents

增加先天免疫反应的化合物和方法 Download PDF

Info

Publication number
CN103957910A
CN103957910A CN201280051347.8A CN201280051347A CN103957910A CN 103957910 A CN103957910 A CN 103957910A CN 201280051347 A CN201280051347 A CN 201280051347A CN 103957910 A CN103957910 A CN 103957910A
Authority
CN
China
Prior art keywords
trifluoromethyl
hydrogen
imidazo
methyl
naphthyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280051347.8A
Other languages
English (en)
Chinese (zh)
Inventor
A.L.班卡
J.博特延什基
E.G.伯勒斯
J.G.卡塔拉诺
W.H.切尔恩
H.D.迪克森
M.J.加特兰德
R.哈马泰克
H.霍夫兰德
J.D.凯彻尔
C.B.摩尔
J.B.肖特维尔
M.D.塔兰特
J-P.瑟里恩
S.尤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline China Investment Co Ltd
Original Assignee
GlaxoSmithKline China Investment Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline China Investment Co Ltd filed Critical GlaxoSmithKline China Investment Co Ltd
Publication of CN103957910A publication Critical patent/CN103957910A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201280051347.8A 2011-10-21 2012-10-19 增加先天免疫反应的化合物和方法 Pending CN103957910A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161549784P 2011-10-21 2011-10-21
US61/549784 2011-10-21
US201261692431P 2012-08-23 2012-08-23
US61/692431 2012-08-23
PCT/US2012/060971 WO2013059559A2 (en) 2011-10-21 2012-10-19 Compounds and methods for enhancing innate immune responses

Publications (1)

Publication Number Publication Date
CN103957910A true CN103957910A (zh) 2014-07-30

Family

ID=48141628

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280051347.8A Pending CN103957910A (zh) 2011-10-21 2012-10-19 增加先天免疫反应的化合物和方法

Country Status (23)

Country Link
US (1) US20140249143A1 (https=)
EP (1) EP2768506A4 (https=)
JP (1) JP2014532626A (https=)
KR (1) KR20140094559A (https=)
CN (1) CN103957910A (https=)
AR (1) AR088793A1 (https=)
AU (1) AU2012325971B2 (https=)
BR (1) BR112014008727A2 (https=)
CA (1) CA2851801A1 (https=)
CL (1) CL2014001016A1 (https=)
CO (1) CO6910198A2 (https=)
CR (1) CR20140175A (https=)
DO (1) DOP2014000081A (https=)
EA (1) EA201490610A1 (https=)
IL (1) IL231894A0 (https=)
MX (1) MX2014004814A (https=)
PE (1) PE20141359A1 (https=)
PH (1) PH12014500865A1 (https=)
SG (2) SG10201505664WA (https=)
TW (2) TW201542567A (https=)
UY (1) UY34406A (https=)
WO (1) WO2013059559A2 (https=)
ZA (1) ZA201402392B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104529893A (zh) * 2014-12-30 2015-04-22 中国科学技术大学 一类可以作为高尔基体细胞器探针的新型喹啉染料
CN105175277A (zh) * 2015-05-18 2015-12-23 中山大学肿瘤防治中心 一种3-磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103333168B (zh) * 2013-07-23 2015-08-05 清华大学 一种酰胺类化合物及其制备方法与应用
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
US10112895B2 (en) 2014-09-29 2018-10-30 The Trustees Of The University Of Pennsylvania Antivirals against molluscum contagiosum virus
WO2018043747A1 (ja) * 2016-09-05 2018-03-08 国立大学法人京都大学 抗ｂ型肝炎ウイルス剤
EP3601286A4 (en) 2017-03-28 2020-09-23 Pimera, Inc. NEW CRYSTALLINE FORMS OF A POL1 INHIBITOR
WO2020083662A1 (en) 2018-10-23 2020-04-30 Basf Se Tricyclic pesticidal compounds
CN114681472B (zh) * 2019-03-13 2023-06-30 中国人民解放军军事科学院军事医学研究院 氨基葡萄糖及其衍生物作为抗病毒药物的应用
EP4136086A1 (en) 2020-04-14 2023-02-22 Basf Se Tricyclic pesticidal compounds
WO2022049521A1 (en) * 2020-09-03 2022-03-10 Glaxosmithkline Intellectual Property Development Limited Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2022175425A1 (en) 2021-02-22 2022-08-25 Glaxosmithkline Intellectual Property Development Limited Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
WO2023049697A1 (en) 2021-09-21 2023-03-30 Incyte Corporation Hetero-tricyclic compounds as inhibitors of kras
CA3234375A1 (en) 2021-10-01 2023-04-06 Incyte Corporation Pyrazoloquinoline kras inhibitors
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
WO2023244672A1 (en) 2022-06-14 2023-12-21 Assembly Biosciences, Inc. 2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
EP4694881A1 (en) * 2023-04-14 2026-02-18 Humanwell Pharmaceutical US, Inc. Monoacylglycerol lipase (magl) inhibitors for the treatment of pain and related medical disorders
WO2025089372A1 (ja) * 2023-10-26 2025-05-01 国立研究開発法人理化学研究所 イソインドリン誘導体
WO2025128898A1 (en) 2023-12-13 2025-06-19 Assembly Biosciences, Inc. Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections
WO2026084955A1 (en) 2024-10-14 2026-04-23 Assembly Biosciences, Inc. Tricyclic heteroaryl compounds useful for enhancing innate immune responses
WO2026084957A1 (en) 2024-10-14 2026-04-23 Assembly Biosciences, Inc. Tricyclic heteroaryl compounds useful for enhancing innate immune responses
WO2026084958A1 (en) 2024-10-14 2026-04-23 Assembly Biosciences, Inc. Tricyclic heteroaryl compounds useful for enhancing innate immune responses

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320126A (zh) * 1998-07-28 2001-10-31 3M创新有限公司 噁唑并、噻唑并和硒唑并[4,5－c]喹啉－4－胺及其类似物
US20050159385A1 (en) * 2003-12-19 2005-07-21 Mohapatra Shyam S. JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
CN1646529A (zh) * 2002-04-03 2005-07-27 霍夫曼-拉罗奇有限公司 咪唑并稠合化合物
WO2010113416A1 (ja) * 2009-03-31 2010-10-07 ダイキン工業株式会社 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE441449B (sv) * 1979-02-09 1985-10-07 Roussel Uclaf Heterocykliska derivat och farmaceutiska kompositioner innehallande dessa derivat
US4492697A (en) * 1983-08-16 1985-01-08 Ayerst, Mckenna & Harrison, Inc. 4H-Imidazo[2,3-c]pyrido[2,3-e][1,4]oxazine derivatives
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
GB0919432D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201002409D0 (en) * 2010-02-12 2010-03-31 Univ Nottingham Methods

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1320126A (zh) * 1998-07-28 2001-10-31 3M创新有限公司 噁唑并、噻唑并和硒唑并[4,5－c]喹啉－4－胺及其类似物
CN1646529A (zh) * 2002-04-03 2005-07-27 霍夫曼-拉罗奇有限公司 咪唑并稠合化合物
US20050159385A1 (en) * 2003-12-19 2005-07-21 Mohapatra Shyam S. JAK/STAT inhibitors and MAPK/ERK inhibitors for RSV infection
WO2010113416A1 (ja) * 2009-03-31 2010-10-07 ダイキン工業株式会社 高分子アクチュエータ素子用電極膜及びそれを有する高分子アクチュエータ素子

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
无: "2-[2,4-二(三氟甲基)咪唑并[1,2-a]1,8-萘啶-8-基]-1,3,4-噁二唑，RN 691868-88-9", 《STN ONLINE：DATABASE REGISTRY》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104529893A (zh) * 2014-12-30 2015-04-22 中国科学技术大学 一类可以作为高尔基体细胞器探针的新型喹啉染料
CN104529893B (zh) * 2014-12-30 2016-08-24 中国科学技术大学 一类可以作为高尔基体细胞器探针的喹啉染料
CN105175277A (zh) * 2015-05-18 2015-12-23 中山大学肿瘤防治中心 一种3-磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用
CN105175277B (zh) * 2015-05-18 2018-04-03 中山大学肿瘤防治中心 一种3‑磷酸甘油醛脱氢酶的抑制剂及其制备方法和应用

Also Published As

Publication number Publication date
CR20140175A (es) 2014-06-03
SG10201505664WA (en) 2015-09-29
PE20141359A1 (es) 2014-10-13
EA201490610A1 (ru) 2014-09-30
TW201333003A (zh) 2013-08-16
PH12014500865A1 (en) 2014-05-26
WO2013059559A3 (en) 2013-11-14
MX2014004814A (es) 2014-05-27
TW201542567A (zh) 2015-11-16
AU2012325971A1 (en) 2014-04-17
BR112014008727A2 (pt) 2017-04-25
US20140249143A1 (en) 2014-09-04
SG11201400988SA (en) 2014-07-30
JP2014532626A (ja) 2014-12-08
DOP2014000081A (es) 2014-07-15
CA2851801A1 (en) 2013-04-25
EP2768506A2 (en) 2014-08-27
ZA201402392B (en) 2017-09-27
KR20140094559A (ko) 2014-07-30
AR088793A1 (es) 2014-07-10
UY34406A (es) 2013-05-31
IL231894A0 (en) 2014-05-28
AU2012325971B2 (en) 2016-03-31
CO6910198A2 (es) 2014-03-31
CL2014001016A1 (es) 2015-01-16
EP2768506A4 (en) 2015-08-19
WO2013059559A2 (en) 2013-04-25

Similar Documents

Publication Publication Date Title
CN103957910A (zh) 增加先天免疫反应的化合物和方法
US10968236B2 (en) TYK2 inhibitors and uses thereof
JP4970048B2 (ja) イミダゾ［４，５−ｃ］ピリジン化合物および抗ウイルス治療の方法
JP5882329B2 (ja) ＤＮＡ−ＰＫ阻害剤としてのイミダゾ［４，５−ｃ］キノリン
JP6336036B2 (ja) ウイルス感染治療のための大環状デアザプリノン
JP5411393B2 (ja) ピラゾロキノリン類
KR20080109095A (ko) Ｆｇｆ 수용체 키나제 억제제를 위한 조성물 및 방법
WO2011031965A1 (en) Modulators of toll-like receptors
JP2005529919A (ja) 治療用化合物
WO2012140114A1 (en) Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent
WO2020154474A1 (en) Tyk2 inhibitors and uses thereof
CN107074880A (zh) 二氢吡啶并吡嗪‑1,8‑二酮和它们在治疗、改善或预防病毒疾病中的用途
WO2022049521A1 (en) Imidazonaphthyridines and imidazopyridopyrimidines as ifnar2 agonists for treating sars-cov-2 infections
WO2008060597A2 (en) Compounds useful as protein kinase inhibitors
JP2005516916A (ja) 抗ヘルペス薬としてのピラゾロ−ピリジン誘導体
WO2014134750A1 (zh) 2,6,9-三取代嘌呤衍生物及其制备方法与应用
CN113045589B (zh) 流感病毒复制抑制剂及其用途
CN116253740A (zh) 环状双苄基异喹啉类化合物及其制备方法和应用
CN115003383A (zh) 干扰素基因刺激物sting的双环激动剂
WO2025128898A1 (en) Imidazo[1,2-a][1,8]naphthyridine derivatives as enhancers of innate immune response for the treatment of viral infections
HK40081945A (en) Bicyclic agonists of stimulator of interferon genes sting
HK40079963B (zh) 含吡啶酮稠环类衍生物抑制剂、其制备方法和应用
HK1248690B (en) Tyk2 inhibitors and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned

Effective date of abandoning: 20180209

AD01 Patent right deemed abandoned